Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16494560 | 0.87 | ACHE (0.46) | FAAHALDH1A1ACHEBCHEEGFR | |
| SCHEMBL16494508 | 0.85 | ACHE (0.60) | FAAHEPHX1ALDH1A1RAB9AACHE | |
| SCHEMBL16494500 | 0.85 | ACHE (0.60) | FAAHEPHX1ALDH1A1RAB9AACHE | |
| SCHEMBL16494442 | 0.82 | ACHE (0.46) | ALDH1A1ACHEEGFRERBB2ERBB4 | |
| SCHEMBL16494107 | 0.81 | ACHE (0.50) | EPHX1ALDH1A1ACHEALOX5EPHX2 | |
| SCHEMBL16494610 | 0.81 | BCHE (0.48) | FAAHEPHX1ALDH1A1RAB9AACHE | |
| SCHEMBL16494244 | 0.81 | EGFR (0.42) | ACHEEPHX2BCHEEGFRERBB2 | |
| SCHEMBL16494443 | 0.80 | ACHE (0.60) | FAAHEPHX1ACHEALOX5EPHX2 | |
| SCHEMBL16494279 | 0.80 | EGFR (0.52) | ALDH1A1RAB9AACHEBCHEEGFR | |
| SCHEMBL16494866 | 0.78 | BCHE (0.55) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | claimed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | claimed |
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | FAAH 202/4885EPHX1 1172/4885ALDH1A1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.